OncoMatch/Clinical Trials/NCT06340204
Weekly Irinotecan Liposomes in Recurrent or Refractory Ewing Sarcoma
Is NCT06340204 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies Irinotecan Hydrochloride Liposome for ewing sarcoma.
Treatment: Irinotecan Hydrochloride Liposome — The investigators explored the safety and activity of weekly irinotecan liposomes in patients with relapsed and metastatic Ewing Sarcoma.
Check if I qualifyExtracted eligibility criteria
Cancer type
Sarcoma
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: cytotoxic chemotherapy (doxorubicin, vincristine, cyclophosphamide, ifosfamide, etoposide) — standard Ewing Sarcoma chemotherapy
Prior treatment consisted of standard Ewing Sarcoma chemotherapy agents including doxorubicin, vincristine, cyclophosphamide, ifosfamide and etoposide
Lab requirements
Blood counts
Adequate organ function. Known persistent (> 4 weeks) ≥ Grade 2 neutropenia, ≥ Grade 2 thrombocytopenia or > Grade 3 anemia from prior cancer therapy [excluded].
Kidney function
Adequate organ function.
Liver function
Adequate organ function.
Adequate organ function. Known persistent (> 4 weeks) ≥ Grade 2 neutropenia, ≥ Grade 2 thrombocytopenia or > Grade 3 anemia from prior cancer therapy [excluded].
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify